natgillin/translations-raw huggingface dataset:
The process of item 6, wherein the extended release matrix formulation is subjected to a temperature of at least about 62 °C or at least about 68 °C for a time period of from about 1 minute to about 5 hours or from about 5 minutes to about 3 hours. 
(2) barem jedan aktivni agens, 1 pri čemu je formulacija matrica s produljenim otpuštanjem stvrdnuta pri temperaturi od barem oko 60 *C u vremenskom periodu od oko 1 minute i ima snagu pucanja od barem oko 110 N kada je podvrgnut indentacijskom tostui.
A method according to claim 1 or 2 characterised in that (-)- O, O' -di- p -toluoyl-(R,R)-tartaric acid is used. 
Postupak prema zahtjevu 1 ili 2, naznačen time, što se upotrebljava (-)-0,0"-di-p-toluoil- (R,R)-vinska kiselina.
an antibody, or antigen binding fragment thereof in which the heavy chain of said antibody, or antigen-binding fragment thereof, contacts amino acid residues in said proximal monomer, and wherein the light chain of said antibody, or antigen-binding fragment thereof, contacts amino acid residues in said proximal monomer and in said distal right monomer of said HA trimer; and 
protutijelo, ili njegov ulomak koji veže antigen u kojem teški lanac navedenog protutijela, ili njegov ulomak koji veže antigen, dolazi u kontakt s aminokiselinskim ostatcima u navedenom proksimalnom monomeru, i pri čemu laki lanac navedenog protutijela, ili njegov ulomak koji veže antigen, dolazi u kontakt s aminokiselinskim ostatcima u navedenom proksimalnom monomeru i u navedenom distalnom desnom monomeru navedenog HA trimera; i
to form a compound having the formula: and 
i ii) deprotekcije tozil grupe da bi se formirao spoj formule 1070.
The article of manufacture according to claim 13, wherein the follicte-stimulating hormone (FSH) is present at a concentration of at or about 0.37 to 2 µg/mg of the total formulation. 
Pripravak prema zahtjevu 13 naznačen time da je hormon za stimulaciju folikula (FSH) prisutan u koncentraciji od ili oko 0.37 do 2 ug/mg ukupne formulacije. .
C1-2alkyl optionally substituted with one group selected from: —OH, —CO2H, 
(A) Cr2alkil opcijski supstituiran s jednom skupinom odabranom od sljedećih: a) b)
Preparation of the compound of formula (I) 
Datum podnošenja europske prijave patenta:
The method of claims 1-9, wherein the protein carrier is selected from the group consisting of: TT, DT, CRM197, fragment C of TT, protein D of H. influenzae, pneumococcal PhtD, and pneumococcal Pneumolysin. 
Postupak u skladu s patentnim zahtjevima 1-9, naznačen time što se proteinski nosač bira iz skupine koju čine: TT, DT, CRM197, fragment C od TT, protein D iz bakterije H. influenzae, pneumokokni PhtD, te pneumokokni pneumolizin.
a polynucleotide sequence having at least 85% sequence identity to the polynucleotide sequence set forth in SEQ ID NO:4 or 8. 
polinukleotidne sekvence koja ima najmanje 85% identiteta sekvence od polinukleotidne sekvence prikazane u SEQ ID NO: 4 ili 8.
A crumb as claimed in any of claims 1 to 10 wherein the gelling agent is guar gum or locust bean gum. 
Mrvice prema bilo kojem od zahtjeva 1 do 12 gdje je sredstvo za geliranje guar guma ili brašno sjemenke rogača.
The process according to any of claims 6 to 13, wherein the drinking yoghurt is filled into suitable containers, and wherein the pH of the drinking yoghurt in the containers is monitored, and when a desired pH has been reached, the temperature is decreased to terminate the fermentation. 
Postupak prema bilo kojem od zahtjeva 6 do 13, gdje se jogurt za piće puni u odgovarajuće spremnike, 1 gdje se pH jogurta za piće u spremnicima nadzire, i kada se postigne željeni pH, temperatura se smanjuje radi zaustavljanja fermentacije.
In this way, the mouthpiece (14) is completely exposed when the mouthpiece cover (2) is switched from the first position to the second position and the gear mechanism is triggered by a drive gear (12). 
Uređaj za inhaliranje prema zahtjevu 1, naznačen time da se poklopac nastavka za usta (2) uređaja za inhaliranje spaja s mehanizmom zupčanika pomoću pogonskog zupčanika (12) preko jedne spojne točke (29) poklopca nastavka za usta. 4.
The non-load transmitting idler gear is maintained in proper mesh contact with the drive gear and driven gear by the suspension mechanism. 
Taj zupčanik ostaje u odgovarajućem kontaktu sa zupcima pogonskog i pogonjenog zupčanika pomoću amortizacijskog mehanizma.
to 250 g per litre PEG having an average molecular weight of 2500 to 4500 Da; 
(i) 70 do 250 g po litri PEG koji ima prosječnu molekularnu težinu od 2500 do 4500 Da; i
A combination of a compound of formula (I) as defined in claims 1 to 7 with a second pharmaceutical active component selected from the classes of B2 agonists, M3 antagonists and corticosteroids. 
Kombinacija spoja formule (I) kao što je definirano u patentnim zahtjevima 1 do 7, naznačena time da je s drugom farmaceutski aktivnom komponentom odabranom od sljedećih: klasa 2 agonista, M3 antagnista i koritkosteroidi.
Preparation of Amorphous Forms of Compound of Formula I 
Kristalni polimorf koji sadrži spoj Formule I:
Thereby, in the completed veneer, by means of said contrast, another decorative effect is consciously achieved. 
Na taj način se u dovršenom furniru, uz pomoć navedenog kontrasta, svjesno postiže drugi dekorativni efekt.
A humanized or chimeric CD37-specific immunoglobulin binding protein, comprising: 
Humanizirani CD37-specifični vezni protein u skladu s patentnim zahtjevom 6, pri čemu:
an at least partially straight shaft (108); 
- barem djelomično ravnu osovinu (108);
is selected from the group consisting of methyl, ethyl, propyl, fluoro, chloro, and trifluoromethyl; 
X se bira iz skupine koju čine O, S, SO2, NH i NCH3;
forward the special data packet with the end marker received from the SGW to the target eNB through the X2 interface. 
pri čemu je završna oznaka postavljena u zaglavlje posebnog paketa podataka da se naznači kraj slanja paketa korisničkih podataka.
Example 1.1: Preparation of the platform formulation buffer 
Broj objave europskog patenta:
The host cell according to claim 3, which is an antigen presenting cell, such as, for example, a dendritic cell. 
Stanica domaćin, sastoji se od nukleinske kiseline ili ekspresijskog vektora u skladu s patentnim zahtjevom 5, koja je stanica koja prezentira antigen.
wherein a compound of formula (3): is allowed to react with ethylenediamine, thereby providing a compound of formula (4). 
(N70 NO, O u oma ostavljen da reagira s etilendiaminom, čime se dobiva spoj s formulom (4).
In a further embodiment forty the present invention provides an antibody or antigen-binding fragment or pharmaceutical composition according to any one of the embodiments 1-37, wherein the use is for the treatment of psoriasis, inflammatory bowel disease, psoriatic arthritis, multiple sclerosis, rheumatoid arthritis, COPD, chronic asthma or ankylosing spondylitis. 
Protutijelo ili njegov fragment koji veže antigen ili farmaceutski pripravak za uporabu prema patentnom zahtjevu 6 ili 7, naznačeni time, da se kod uporabe u medicini radi o uporabi u postupku liječenja psorijaze, upalne bolesti crijeva, psorijatičkog artritisa, multiple skleroze, reumatoidnog artritisa, KOPB-a, kronične astme ili ankiloznog spondilitisa.
The composition of claim 3, wherein the protein is MRP2, BCR-ABL, STI-571 resistance-associated protein, lung resistance-related protein, cyclooxygenase-2, nuclear factor kappa, XRCC1, ERCC1, GSTP1, mutant B-tubulin, or a growth factor. 
Sastav zahtjeva 3, time naznačeno da je protein MRP2, BCR-ABL, STI-571 povezan sa stvaranjem otpornosti, LRP (lung resistance related protein), ciklooksigenaza-2, nuklearni čimbenik kapa, XRCC1, ERCC1, GSTP1, mutant B-tubulin ili čimbenik rasta.
Dosage form according to any of claims 1 to 5 in tablet form, comprising as excipients for the tablet core sodium carbonate, mannitol, crospovidone, low molecular weight polyvinylpyrrolidone, and magnesium or calcium stearate. 
Dozirni oblik prema bilo kojem od zahtjeva 1 do 4, naznačen time, da on sadrži sljedeća pomoćna sredstva za tabletnu jezgru: natrijev karbonat, manitol, krospovidon, polivinilpirolidon lagane molekularne težine, te magnezijev ili kalcijev stearat.
Security element according to claim 6, wherein said magnetic optically variable interference pigments are selected from the group consisting of vacuum deposited magnetic thin film interference pigments, interference coated metallic pigments, interference coated non-metallic pigments, magnetic liquid crystal pigments, and mixtures thereof. 
Sigurnosni element prema jednom zahtjevu od 1 do 5, naznačen time da su navedeni magneto-optički promjenjivi interferencijski pigmenti odabrani iz skupine koja sadrži vakuumski položene interferencijske pigmente u magnetskom tankom filmu, interferencijski prevučene metalne pigmente, interferencijski prevučene nemetalne pigmente, magnetske tekuće kristalne pigmente, te njihove smjese.
coating the core using an inner coating preparation comprising a third polymeric material that is soluble in intestinal fluid or gastrointestinal fluid, in a solvent system to form an inner coated core and; coating the inner coated core with an outer coating preparation comprising a first polymeric material which is susceptible to attack by colonic bacteria and a second polymeric material which has a pH threshold of pH 6 or above in a solvent system, to form an outer coated core, 
oblaganje jezgre upotrebom unutarnjeg preparata za oblaganje sadrži treći polimerni materijal koji je topiv u crijevnoj tekućini, u sustavu otapala da se formira unutrašnje obložena jezgra; i oblaganje unutarnje obložene jezgre s vanjskim premaznim pripravkom sadrži prvi polimerni materijal koji je osjetljiv na napad bakterija debelog crijeva i drugi polimerni materijal koji ima pH granicu od pH 6,5 ili više u sustavu otapala, da se dobije vanjska obložena jezgra;
Examples of compounds of formulae II, III and IV are e.g. 
Primjeri spojeva formule II, III 1 IV su na primjer
The method in accordance with claim 4, wherein the application of the electric field is stopped before the conductive pathway has connected the alignment electrodes. 
Postupak u skladu s patentnim zahtjevom 3, 5, 6 ili 7 naznačen time što se korak poravnavanja prekida prije nego vodljivi put dosegne kroz sloj i spoji s poravnavajućim elektrodama.
conditioning and priming of the resulting drug delivery device to achieve the desired delivery rates for the one or more active ingredients; wherein the sealing of the open end, is done by inserting a pre-fabricated end plug at the open end of the hollow tube or by using light or heat. 
€) podešavanje i početno nalijevanje dobijenog uređaja za oslobađanje lijeka da se postignu željene stope oslobađanja jednog ili više aktivnih sastojaka; pri čemu je zaptivanje otvorenog kraja, izvedeno umetanjem unaprijed pripremljenog krajnjeg čepa na otvorenom kraju šuplje cijevi ili primjenom svijetlosti ili topline.
0.3 U/kg arginine-vasopressin (AVP)(Sigma Chemicals, St Louis, Mo, USA) was injected into the carotid artery to induce vasoconstriction of small coronary arteries and increase in coronary resistance. 
U karotidnu arteriju je ubrizgano 0,3 U/kg arginin-vazopresina (AVP)(Sigma Chemicals, St Louis, Mo, USA) da se izazove vazokonstrikciju malih koronarnih arterija i poveća koronarni otpor.
The method according to any of the preceding claims, wherein a filter belt covers at least a part of the surface of the pore roller, such as a filter belt surrounding the surface of the pore roller. 
Postupak prema jednom od prethodno navedenih zahtjeva, naznačen time da filtarska traka pokriva barem dio površine valjka s porama, osobito filtarska traka koja obuhvaća površinu valjka s porama.
Preferably, C1-C8-haloalkyl is C1-C4-alkyl substituted by one, two or three fluorine, bromine or chlorine atoms. 
Ponajprije, Ci-Cg-haloalkil je C;-C2-alk1l supstituiran s jednim, dva ili tri fluorova, bromova ili klorova atoma.
A synthetic method comprising: combining a composition comprising an aprotic solvent and a hydroxy-terminated, water-soluble polymer having the following structure: 
(b) sjedinjavanje kompozicije, koja sadrži aprotonsko otapalo i vodotopljivi polimer sa hidroksi grupom na kraju lanca, koji ima slijedeću strukturu:
and wherein said oxime linkage formation is catalyzed by the nucleophilic catalyst m-toluidine. 
i pri čemu je spomenuto formiranje vezanja oksima katalizirano nukleofilnim katalistom m-toluidinom.
A compound of Formula (I) or a pharmaceutically acceptable salt thereof; 
Spoj, naznačen time, da ima formulu (I) [image] ili njegova farmaceutski prihvatljiva sol;
Process for the preparation of complexes of iron (III) hydroxide and activated glucose syrup, wherein the molecular weight of the complex is in the range of from 50 kDa to 250 kDa, said complex has an iron content of in the range from 27 to 35 wt.% and has more than two -COOH groups per activated glucose syrup molecule, said process comprising the steps: 
Proces za pripremu kompleksnih spojeva željezo (III) hidroksida i aktiviranog glukoznog sirupa, pri čemu je molekularna težina kompleksa u rasponu od 100 kDa do 150 kDa, kako je izmjereno tekućinskom kromatografijom visokog učinka - gel permeacijskom kromatografijom (HPLC-GPC), naveden process sadrži slijedeće korake:
The blood flow was controlled during the 60 min later to the application of the patch in the artery. 
Protok krvi kontroliran je tijekom 60 min nakon aplikacije flastera u arteriju.
is an optionally substituted monocyclic or bicyclic aryl or heteroaryl, wherein each ring is a 5, 6, or 7 membered ring and the optional substitution is halo, cyano, C1-C6 alkyl, C1-C6 branched alkyl, halogenated C1-C6 alkyl, hydroxyl, C1-C6 alkyloxy, amino, or C1-C6 alkylamino. 
Bs je opcionalno supstituirani monociklički ili biciklički aril ili heteroaril, pri čemu je svaki prsten 5, 6 ili 7 člani prsten i opcionalna supstitucija je halo, cijano, C,-C4 alkil, Ci-Cg razgranati alkil, halogenirani C;-Cg alkil, hidroksil, Ci-Cg alkoksi, amino ili Ci-Cg alkilamino.
The wine decanter device of claim 10, wherein said leveling means of the base (10) comprise feet with adjustable height, substantially comprising screws with vertical axis (11) engaged into threaded holes obtained in the base (10). 
Uređaj za pretakanje vina prema patentnom zahtjevu 10, u čemu, spomenuto samonivelirajuće sredstvo postolja (10) sadrži stopice s podesivom visinom, pretežno sadrže vijke s vertikalnom osi (11) spregnutom u navojnim otvorima dobivenim u ovoj bazi (10).
In other embodiments, the present invention provides a pharmaceutical composition comprising (i) a therapeutically effective amount of mature human type I elastase (ii) a pharmaceutically acceptable carrier, which pharmaceutical composition is substantially free of bacterial proteins and/or is substantially free of mammalian proteins other than said mature human type I elastase. 
(1i) farmaceutski sastav je bez proteina sisara, osim spomenute zrele protein elastaze; (111) količina endotoksina u spomenutom farmaceutskom sastavu ne prelazi farmaceutski prihvatljivu količinu, ne prelazi 10 EU po gramu elastaze tipa I elastaze ili ne prelazi 5 EU po gramu tipa I elastaze;
As used herein the term “non aromatic heterocycle” denotes a five or six membered heterocyclic ring, containing one or two heteroatoms, selected from the group consisting of O, N or S. Examples of such rings are 1-pyrrolidine, 1-piperidine, 1-piperazine or 1-morpholine. 
R* je nearomatski heterocikl, termin "nearomatski heterocikl" označava heterociklički prsten s pet ili šest članova koji sadrži jedan ili dva heteroatoma, izabranih iz skupine koja se sastoji od O, Nili Silije OR' ili N(R"),;
The collection according to any one of the preceding claims, wherein said antibodies or functional fragments thereof comprise one or more complementarity determining regions comprising amino acid modifications that remove potential post translational modification sites. 
Zbirka u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što navedena protutijela, ili njihovi funkcionalni fragmenti, sadrže jedno 1li više područja određivanja komplementarnosti koja sadrže aminokiselinske modifikacije koje uklanjaju potencijalna mjesta posttranslacijskih modifikacija.
A toothbrush (10) to claim 2 or 3 in which the first and second axes pass through the centre of the head (12). 
Četkica za zube (10) sukladno zahtjevu 2ili 3 pri čemu prva i druga os prolaze sredinom glave (12).
The method of item 29, wherein the plasma-derived protein is a protein of the complement system. The method of item 34, wherein the protein of the complement system is selected from the group consisting of Factor H (FH), Factor D, complement protein C3, and C4 binding protein. 
Postupak prema bilo kojem od zahtjeva 1 do 11, naznačen time, da protein koji je izveden iz plazme, jest protein iz komplementarnog sustava, te je pritom taj protein iz komplementarnog sustava odabran iz skupine koju čine:
The user can accurately move the rounded end 8 to the vicinity of the cervix. 
Korisnica može točno pomicati zaobljeni karaj 8 do blizine grlića maternice.
A kit comprising: a container that contains a pharmaceutical composition containing a peptide according to any one of claims 1 to 4, the nucleic acid or the expression vector according to claim 5, a cell according to claim 7, or an activated cytotoxic T lymphocyte according to claim 10, in solution or in lyophilized form; 
(a) Kutije koja sadrži farmaceutski sastav koji se sastoji od peptida u skladu s bilo kojim zahtjevom 1 - 4, nukleinske kiseline ili ekspresijskog vektora u skladu s patentnim zahtjevom 5, stanice u skladu s patentnim zahtjevom 7 ili 8, ili aktiviranog citotoksičnog T-limfocita u skladu s patentnim zahtjevom 11, u otopini ili liofiliziranom obliku; i
The resulting mixture was extracted with diethyl ether (3x50 mL). 
Dobivenu smjesu ekstrahira se dietil-eterom (3 x 50 ml).
In yet another embodiment the cell culture used in the production process is essentially free of any supplements derived from animals, such as cod liver oil supplements. 
Postupak u skladu s patentnim zahtjevom 10, naznačen time što kultura stanica uglavnom ne sadrži nikakve dodatke dobivene iz životinja, poput ulja od bakalarove jetre kao dodatka.
ST2472 in rat microsomes was almost exclusively metabolized to M2 (FIG. 3); therefore it may be hypothesized that metabolites M1 and M2 arise from ST1899 and ST2472 metabolism, respectively. 
ST2472 u mikrosomima štakora gotovo se isključivo metabolizirao u M2 (Slika 3); zbog toga se može pretpostaviti da metaboliti MI 1 M2 nastaju iz ST1899, odnosno ST2472 metabolizma.
Dose Volume Number of Animals 
Broj međunarodne prijave:
The method of claim 1, wherein the disease is psoriatic arthritis. 
Spoj za uporabu prema zahtjevu 11, naznačen time što je bolest psorijazni artritis.
In the case of the SU-MIMO transmission, where the two CWs (CW#0 and CW#1) are transmitted in a plurality of layers, resource amount determining section 204 determines the amount of resource for each of the plurality of layers, the amount of the resource being allocated to control information (ACK/NACK signals) allocated in the two CWs (CW#0 and CW#1). 
Uređaj bazna stanica (100) koji prima kontrolnu informaciju u pluralitetu slojeva, uređaj sadržeći: sekciju prijema (107) koja prima signal koji uključuje kontrolnu informaciju; 1 sekciju vađenja kontrolne informacije (111) koja određuje količinu resursa kontrolne informacije u pluralitetu slojeva i ekstrahira kontrolnu informaciju iz primljenog signala na temelju količine resursa kontrolne informacije, naznačeno time da je količina resursa Qcwso+cws1 kontrolne informacije određena jednadžbom 1:
The method wherein the adverse reaction is grades 3 or 4 thrombocytopenia. 
Postupak prema zahtjevu 4, pri čemu je neželjena reakcija stupanj 3 ili 4 trombocitopenije.
The antibody or a-synuclein binding fragment thereof of claim 3 for use according to claim 11, wherein the synucleinopathic disease is Parkinson's disease. 
Protutijelo ili njegov fragment koji veže a-sinuklein u skladu s patentnim zahtjevom 3 za uporabu u skladu s patentnim zahtjevom 11, naznačen time da je sinukleinpatska bolest Parkinsonova bolest.
The vessel according to claim 19, having a top transverse plate (2) extending at an angle (R) obliquely upwards, wherein said angle (R) is dependent of a distance between a hull of the and the top transverse plate (2). 
Objekt sličan brodu u skladu s patentnim zahtjevom 14, ima gornju poprečnu ploču (2) koja se pod kutem ((B) nastavlja koso prema gore, pri čemu je navedeni kut (B) ovisan o udaljenosti između trupa objekta sličnog brodu i gornje poprečne ploče(2).
pneumatically actuating the ERC upon receipt of the radio signal, wherein actuating the ERC decouples the conduit. The method of claim 8, wherein the radio signal is initiated by the computer (82) or the PLC. 
Postupak prema zahtjevu 8, naznačen time da je radio signal iniciran od strane računala (82), pri čemu računalo (82) obrađuje podatke primljene od prvog i drugog transpondera (80).
an amino acid sequence consisting of amino acid residues 21 to 258 of the amino acid sequence represented by SEQ ID NO: 4 in the Sequence Listing. A monoclonal antibody or a functional fragment thereof which specifically recognizes one or more Siglec-15 polypeptides consisting of an amino acid sequence encoded by a nucleotide sequence described in any one of the following (j) to (m) and inhibits osteoclast formation and/or osteoclastic bone resorption: 
Monoklonsko antitijelo ili njegov funkcionalni fragment koji specifično prepoznaju jedan ili više siglec-15 polipeptida s aminokiselinskim slijedom kodiranim nukleotidnim slijedom, koji je opisan bilo kojom od sljedećih stavki i) do 1), i koji inhibiraju razvoj osteoklasta i/ili osteoklastnu resorpciju kostiju: i) -onukleotidni slijed predstavljen kao SEQ ID NO: 1; j) -nukleotidni slijed predstavljen kao SEQ ID NO: 3; k) nukleotidni slijed predstavljen kao SEQ ID NO: 19:1
The reactions were worked up by diluting the reaction solution in 20mL EtOAc and washing with water until the pH of the water washes was approximately 7. 
Rcakcije su bile dorađenc razrjeđivanjem reakcijske otopine u 20 mL EtOAc 1 ispirane vodom dok pH vode od ispiranja nije bio približno 7.
The compound or salt or pharmaceutical composition for the use of Claim 20, wherein said method comprises administration of said compound or salt or said pharmaceutical composition by an oral, parenteral, sublingual, buccal, intranasal, pulmonary, topical, transdermal, intradermal, ocular, otic, rectal, vaginal, intragastric, intracranial, intrasynovial or intra-articular route. 
Spoj ili sol ili farmaceutski pripravak za uporabu u skladu s patentnim zahtjevom 20, naznačen time, da navedeni postupak obuhvaća davanje navedenog spoja ili soli ili farmaceutskog pripravka oralnim, parenteralnim, sublingvalnim, bukalnim, intranazalnim, plućnim, topikalnim, transdermalnim, intradermalnim, okularnim, otičnim, rektalnim, vaginalnim, intragastričnim, intrakranijskim, intrasinovialnim ili intraartikularnim putem.
W is a group of formula (Wc) wherein 
W je skupina formule (WC) £
The compound, composition or dosage form according to claim 7, wherein the cancer is selected from lung cancer including non-small cell lung cancer and small cell lung cancer, colon cancer, breast cancer, pancreas cancer, sarcoma, ovarian cancer, prostate cancer and gastric cancer. 
Sjedinjenje, kompozicija ili dozni oblik u skladu sa patentnim zahtjevom 7, gdje je rak odabran od raka pluća uključujući rak pluća malih stanica i rak pluća nemalih stanica, rak debelog crijeva, kolorektalnog raka, raka dojke, raka gušterače, sarkoma, raka jajnika i raka želuca.